Reuters logo
6 months ago
BRIEF-Tracon Pharmaceuticals announces top-line results from NCI-sponsored Phase 2 trial of TRC105
February 9, 2017 / 9:38 PM / 6 months ago

BRIEF-Tracon Pharmaceuticals announces top-line results from NCI-sponsored Phase 2 trial of TRC105

Feb 9 (Reuters) - Tracon Pharmaceuticals Inc

* Tracon Pharmaceuticals announces top-line results from NCI-sponsored Phase 2 trial of TRC105 in recurrent glioblastoma

* Tracon Pharma - combination of TRC105, Avastin did not improve median progression free survival versus single agent avastin in recurrent glioblastoma patients

* Tracon Pharmaceuticals Inc - combination of TRC105 and avastin was associated with a non-significant increase in overall survival Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below